Myeloproliferative Neoplasms News

The FDA granted orphan drug designation to TP-3654 for the treatment of myelofibrosis.

Aaron T. Gerds, MD, MS, spoke with Healio about the REVEAL study, results of which were presented at this year’s European Hematology Association Congress.

CHICAGO – Healio gathered the best, brightest and boldest group of oncologists during the ASCO Annual Meeting in Chicago to celebrate our inaugural Healio Disruptive Innovators.

In its 2022 Cancer Disparities Progress Report, American Association for Cancer Research discussed advances made in closing substantial gaps in care while underscoring the need for further progress.

Momelotinib demonstrated statistically significant improvement in anemia measures, splenic response and total symptom score compared with danzol among patients with previously treated myelofibrosis, according to study results.

Women demonstrated a 34% increased risk for severe adverse events from any cancer treatment compared with men, according to a study published in Journal of Clinical Oncology.

Treatment with a hypomethylating agent may activate or upregulate SALL4, an oncogene that plays a key role in myelodysplastic syndrome and other cancers, according to study results published in The New England Journal of Medicine.

First responders to the World Trade Center had higher rates of clonal hematopoiesis-associated mutations than firefighters not exposed to the dust, gases and potential carcinogens at the site, according to a study in Nature Medicine.

ASCO and the Association of Community Cancer Centers have jointly developed recommendations for improving equity, diversity and inclusion in cancer clinical trials.

The FDA placed a partial clinical hold on a phase 1 dose-escalation study of a therapy under investigation for certain patients with blood cancer.